CHAMPIONS ONCOLOGY, INC.
For the period ended Aug 27, 2026. Filed Aug 28, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Aug 27, 2026 · Filed Aug 28, 2026
Contents
Outstanding Equity Awards at 2026 Fiscal Year End
The following table sets forth, for each of the named executive officers named in the Summary Compensation Table, information with respect to unexercised options as of the Company’s fiscal year ended April 30, 2026:
| Name | Number of SecuritiesUnderlyingUnexercised Options(#) Exercisable | Number of SecuritiesUnderlyingUnexercised Options(#) Unexercisable | OptionExercise Price($) | Option ExpirationDate (1) |
|---|---|---|---|---|
| Ronnie Morris, M.D. (2) | 279,177 | — | $1.60 | 10/28/2026 |
| 132,565 | — | $2.51 | 7/27/2027 | |
| Robert Brainin (3) | 8,032 | — | 9.27 | 6/9/2031 |
| 9,901 | — | 10.10 | 11/5/2031 | |
| 14,130 | — | 7.00 | 11/1/2032 | |
| 19,070 | — | 5.51 | 11/3/2033 | |
| 23,030 | — | 4.64 | 11/12/2034 | |
| — | 225,000 | $7.80 | 7/16/2035 | |
| — | 62,500 | $7.80 | 7/16/2035 | |
| — | 62,500 | $7.80 | 7/16/2035 | |
| — | 150,000 | $7.80 | 7/16/2035 | |
| — | 100,000 | $7.80 | 7/16/2035 | |
| — | 100,000 | $7.80 | 7/16/2035 | |
| David Miller (4) | 25,000 | — | $2.10 | 7/19/2026 |
| 10,000 | — | $2.51 | 7/27/2027 | |
| 12,500 | — | $3.62 | 4/9/2028 | |
| 25,000 | — | $5.23 | 10/31/2029 | |
| 6,000 | — | $7.05 | 9/10/2030 | |
| 5,000 | — | $8.98 | 6/23/2031 | |
| 10,000 | — | $7.57 | 6/23/2032 | |
| 2,500 | — | $6.11 | 7/6/2033 | |
| 3,000 | — | $4.25 | 9/5/2034 | |
| — | 15,000 | 5.72 | 6/2/2035 |
(1)All vested options will be exercisable over a ten-year period expiring on the tenth anniversary of the grant date, subject to earlier termination upon certain events.
(2)Comprised of 279,177 options issued on October 28, 2016 and 132,565 options issued on July 27, 2017.
(3)Comprised of 8,032 options issued on June 9, 2021, 9,901 options issued on November 5, 2021, 14,130 options issued on November 1, 2022, 19,070 options issues on November 5, 2023, and 23,030 options issued on November 12, 2024, all of which were granted to Mr. Brainin where his role with the Company was solely as a Board director. Additionally comprised of 700,000 options issued on July 16, 2025 to Mr. Brainin as part of his employment agreement and solely related to his new role of Chief Executive Officer.
(4)Comprised of 25,000 options issued on July 19, 2016, 10,000 options issued on July 27, 2017, 12,500 options issued on April 9, 2018, 25,000 options issued on October 31, 2019, 6,000 options issued on September 10, 2020, 5,000 options issued on June 23, 2021, 10,000 options issued on June 23, 2022, 2,500 options issued on July 6, 2023, and 3,000 options issued on September 5, 2024, and 15,000 options issued on June 2, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.